ARTICLE | Clinical News
MDV3100: Completed Phase III enrollment
December 6, 2010 8:00 AM UTC
Medivation and Astellas completed enrollment of 1,199 patients in the double-blind, placebo-controlled, international Phase III AFFIRM trial evaluating once-daily 160 mg oral MDV3100. Last year, the c...